Michael Grondine

1.4k total citations
14 papers, 544 citations indexed

About

Michael Grondine is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Michael Grondine has authored 14 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in Michael Grondine's work include Cancer Mechanisms and Therapy (4 papers), Cancer therapeutics and mechanisms (3 papers) and DNA Repair Mechanisms (3 papers). Michael Grondine is often cited by papers focused on Cancer Mechanisms and Therapy (4 papers), Cancer therapeutics and mechanisms (3 papers) and DNA Repair Mechanisms (3 papers). Michael Grondine collaborates with scholars based in United States, United Kingdom and Singapore. Michael Grondine's co-authors include Stephen Green, Chun Deng, Candice L. Horn, Sonya Zabludoff, James W. Janetka, Susan Ashwell, Karen J. Taylor, Shannon Ready, Archie Tse and Elizabeth Mouchet and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Michael Grondine

14 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Grondine United States 8 421 265 76 67 63 14 544
Candice L. Horn United States 6 457 1.1× 251 0.9× 81 1.1× 55 0.8× 64 1.0× 10 552
Anuj Manandhar United States 4 498 1.2× 195 0.7× 69 0.9× 54 0.8× 54 0.9× 4 604
Martine B.W. Prinsen Netherlands 11 270 0.6× 151 0.6× 98 1.3× 80 1.2× 65 1.0× 19 456
Gretchen A. Repasky United States 8 403 1.0× 200 0.8× 63 0.8× 44 0.7× 95 1.5× 9 634
Jeff Kucharski United States 6 534 1.3× 216 0.8× 47 0.6× 94 1.4× 46 0.7× 10 656
Sherif Tawfic United States 15 653 1.6× 270 1.0× 62 0.8× 74 1.1× 81 1.3× 21 798
Lora A. Tucker United States 13 326 0.8× 242 0.9× 56 0.7× 84 1.3× 88 1.4× 15 577
Barbara Hibner United States 6 391 0.9× 223 0.8× 41 0.5× 64 1.0× 59 0.9× 11 519
Alexis de Haven Brandon United Kingdom 12 424 1.0× 179 0.7× 39 0.5× 81 1.2× 122 1.9× 22 595
Yahao Bu United States 12 323 0.8× 146 0.6× 83 1.1× 43 0.6× 63 1.0× 16 515

Countries citing papers authored by Michael Grondine

Since Specialization
Citations

This map shows the geographic impact of Michael Grondine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Grondine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Grondine more than expected).

Fields of papers citing papers by Michael Grondine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Grondine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Grondine. The network helps show where Michael Grondine may publish in the future.

Co-authorship network of co-authors of Michael Grondine

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Grondine. A scholar is included among the top collaborators of Michael Grondine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Grondine. Michael Grondine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Xu, Wendan, Philipp Berning, Tabea Erdmann, et al.. (2022). mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma. Leukemia. 37(1). 178–189. 18 indexed citations
2.
Criscione, Steven W., Matthew J. Martin, Derek B. Oien, et al.. (2022). The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. npj Precision Oncology. 6(1). 95–95. 22 indexed citations
3.
Reddy, Venkatesh Pilla, Rana Anjum, Michael Grondine, et al.. (2020). The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST. Clinical Cancer Research. 26(14). 3751–3759. 9 indexed citations
4.
5.
6.
Yang, Bin, Melissa M. Vasbinder, Alexander W. Hird, et al.. (2018). Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. Journal of Medicinal Chemistry. 61(3). 1061–1073. 20 indexed citations
7.
Cidado, Justin, Minhui Shen, Michael Grondine, et al.. (2016). Abstract 3572: AZ5576, a novel potent and selective CDK9 inhibitor, induces rapid cell death and achieves efficacy in multiple preclinical hematological models. Cancer Research. 76(14_Supplement). 3572–3572. 3 indexed citations
8.
Guichard, Sylvie M., Jon Curwen, Teeru Bihani, et al.. (2015). AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Molecular Cancer Therapeutics. 14(11). 2508–2518. 103 indexed citations
9.
10.
Oza, Vibha, Susan Ashwell, Patrick Brassil, et al.. (2012). Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(6). 2330–2337. 19 indexed citations
11.
Keeton, Erika Krasnickas, Kristen McEachern, Marat Alimzhanov, et al.. (2012). Abstract 2796: Efficacy and biomarker modulation by AZD1208, a novel, potent and selective pan-Pim kinase inhibitor, in models of acute myeloid leukemia. Cancer Research. 72(8_Supplement). 2796–2796. 3 indexed citations
12.
Keeton, Erika Krasnickas, Sangeetha Palakurthi, Marat Alimzhanov, et al.. (2011). AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia. Blood. 118(21). 1540–1540. 8 indexed citations
13.
Zabludoff, Sonya, Chun Deng, Michael Grondine, et al.. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Molecular Cancer Therapeutics. 7(9). 2955–2966. 333 indexed citations
14.
Ashwell, Susan, Benjamin Caleb, Chun Deng, et al.. (2007). Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases. Molecular Cancer Therapeutics. 6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Candice L. Horn Breakdown of academic impact, for papers by Anuj Manandhar Breakdown of academic impact, for papers by Martine B.W. Prinsen Breakdown of academic impact, for papers by Gretchen A. Repasky Breakdown of academic impact, for papers by Jeff Kucharski Breakdown of academic impact, for papers by Sherif Tawfic Breakdown of academic impact, for papers by Lora A. Tucker Breakdown of academic impact, for papers by Barbara Hibner Breakdown of academic impact, for papers by Alexis de Haven Brandon Breakdown of academic impact, for papers by Yahao Bu
Rankless by CCL
2026